<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999219</url>
  </required_header>
  <id_info>
    <org_study_id>6199-CL-0006</org_study_id>
    <nct_id>NCT00999219</nct_id>
  </id_info>
  <brief_title>A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia</brief_title>
  <official_title>FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the efficacy and safety of FK199B (Zolpidem MR Tablet) by&#xD;
      polysomnography in patients with insomnia, excluding patients with schizophrenia or&#xD;
      manic-depressive psychosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep parameters estimated from polysomnography recording (wake time after sleep onset and number of awakenings)</measure>
    <time_frame>8 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean sleep parameters estimated from polysomnography recording</measure>
    <time_frame>8 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep parameters estimated from sleep questionnaire</measure>
    <time_frame>After each night of sleep during the study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient impression from sleep questionnaire</measure>
    <time_frame>After each night of sleep during the study period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Sleep Initiation and Maintenance Disorders</condition>
  <arm_group>
    <arm_group_label>FK199B-first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Zolpidem-first group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FK199B</intervention_name>
    <description>oral</description>
    <arm_group_label>FK199B-first group</arm_group_label>
    <arm_group_label>Zolpidem-first group</arm_group_label>
    <other_name>Zolpidem MR Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem</intervention_name>
    <description>oral</description>
    <arm_group_label>FK199B-first group</arm_group_label>
    <arm_group_label>Zolpidem-first group</arm_group_label>
    <other_name>Myslee</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is diagnosed as a primary insomnia according to the Diagnostic and Statistical&#xD;
             Manual of Mental Disorders, Fourth Edition (DSM-IV)&#xD;
&#xD;
          -  Patients complaining of insomnia continuously for 4 weeks or longer&#xD;
&#xD;
          -  Patient's usual bedtime is between 9 p.m. and 12 a.m. for the 4 week period prior to&#xD;
             initial screening&#xD;
&#xD;
          -  Patient on most occasions sleeps for a total of ≥3 and &lt;6.5 hours over the 4 week&#xD;
             period prior to initial screening&#xD;
&#xD;
          -  Patient's usual wake time after sleep onset in a single night is ≥45 minutes per night&#xD;
             for the 4 week period prior to initial screening&#xD;
&#xD;
          -  Patients have a body weight of ≥45 kg and ≤85 kg, a BMI of ≥18.5 and &lt;30&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with schizophrenia or manic-depressive psychosis&#xD;
&#xD;
          -  Patients with insomnia caused by physical diseases including chronic obstructive&#xD;
             pulmonary disease, bronchial asthma, fibrositis syndrome, chronic fatigue syndrome,&#xD;
             rheumatic disease, climacteric disturbance, and dermatitis atopic&#xD;
&#xD;
          -  Patients with circadian rhythm sleep disorder&#xD;
&#xD;
          -  Patient works night shifts&#xD;
&#xD;
          -  Patients with alcoholic sleep disorder&#xD;
&#xD;
          -  Patients with alcohol or drug dependence or a history of these&#xD;
&#xD;
          -  Patients with insomnia related with drugs including antiparkinson, antihypertensive,&#xD;
             or steroid drugs&#xD;
&#xD;
          -  Patients with sleep apnea syndrome&#xD;
&#xD;
          -  Patients with restless legs syndrome or periodic limb movement disorder&#xD;
&#xD;
          -  Patients with epileptic insomnia&#xD;
&#xD;
          -  Patients smoke on average 40 or more cigarettes a day&#xD;
&#xD;
          -  Patients who had received psychotropic drugs other than hypnotics (including&#xD;
             anxiolytic or antidepressant drugs for hypnotic effect) within a 4 week period prior&#xD;
             to the initial screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Touhoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140535 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FK199B</keyword>
  <keyword>Zolpidem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

